Sign In to View Organizational & Contract Pricing.
Select a Size
Change View
About This Item
UNSPSC Code:
12352203
NACRES:
NA.43
eCl@ss:
32160702
Conjugate:
unconjugated
Clone:
polyclonal
Application:
IP, WB
Citations:
2
biological source
rabbit
Quality Level
conjugate
unconjugated
antibody form
purified antibody
antibody product type
primary antibodies
clone
polyclonal
species reactivity
human, rat, mouse
technique(s)
immunoprecipitation (IP): suitable, western blot: suitable
NCBI accession no.
UniProt accession no.
shipped in
wet ice
target post-translational modification
unmodified
Gene Information
human ... JAK2(3717)
mouse ... Jak2(16452)
rat ... Jak2(24514)
General description
Tyrosine-protein kinase JAK2 (EC 2.7.10.2; UniProt Q62120; also known as JAK-2, Janus kinase 2) is encoded by the Jak2 (also known as Fd17) gene (Gene ID 16452) in murine species. JAK2 belongs to the family of non-receptor Janus tyrosine kinases that regulate a spectrum of cellular functions downstream of activated cytokine receptors in the lympho-hematopoietic system. Immunological stimuli, such as interferons and cytokines cause the recruitment of Stat transcription factors to cytokine receptor. Subsequent phosphorylation by receptor-associated JAK2 causes Stat dimerization, nuclear translocation, and Stat-mediated target genes transcription. The canonical JAK/Stat pathway is integral to maintaining a normal immune system by stimulating proliferation, differentiation, survival, and host resistance to pathogens. Altering JAK/Stat signaling to reduce immune cells cytokine responses represents an attractive target for anti-inflammatory therapies. Within the JAK2 kinase domain, there is a region that has considerable sequence homology to the regulatory region of the insulin receptor.
~130 kDa observed. Uncharacterized band(s) may appear in some lysates.
Immunogen
Epitope: Residues 758-776
KLH-conjugated linear peptide corresponding to residues 758-776 of mouse JAK2.
Application
Research Category
Signaling
Signaling
Research Sub Category
Developmental Signaling
Developmental Signaling
Physical form
Format: Purified
Protein A purified
Purified rabbit polyclonal antibody in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.
Preparation Note
Stable for 1 year at 2-8°C from date of receipt.
Analysis Note
Evaluated by Western Blotting in RAW264.7 cell lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected JAK2 in 10 µg of RAW264.7 cell lysate.
Western Blotting Analysis: 0.5 µg/mL of this antibody detected JAK2 in 10 µg of RAW264.7 cell lysate.
Other Notes
Concentration: Please refer to lot specific datasheet.
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Still not finding the right product?
Explore all of our products under Anti-JAK2 Antibody
— or —
Try our Product Selector Tool to narrow your options
Storage Class
12 - Non Combustible Liquids
wgk
WGK 1
flash_point_f
Not applicable
flash_point_c
Not applicable
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Ning Ding et al.
Environmental and molecular mutagenesis, 60(4), 308-319 (2018-12-15)
At sites of chronic inflammation epithelial cells undergo aberrant DNA methylation that contributes to tumorigenesis. Inflammation is associated with an increase in reactive oxygen species (ROS) that cause oxidative DNA damage, which has also been linked to epigenetic alterations. We
Hiroki Akiyama et al.
Cancers, 12(2) (2020-02-14)
JAK2-V617F plays a key role in the pathogenesis of myeloproliferative neoplasm. However, its inhibitor ruxolitinib has shown limited clinical efficacies because of the ruxolitinib-persistent proliferation of JAK2-V617F-positive cells. We here demonstrate that the USP9X inhibitor WP1130 or EOAI3402143 (G9) inhibited